Previous 10 | Next 10 |
Lucid Diagnostics and Collaborators Present New EsoGuard® and EsoCheck® Data at Digestive Disease Week® (DDW) 2023 Conference PR Newswire EsoGuard ® continues to demonstrate excellent esophageal precancer and cancer detection performance, including in m...
2023-05-07 10:45:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2023-04-27 18:45:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
PAVmed Digital Health Subsidiary, Veris Health, Appoints Gary Manning as President PR Newswire Manning Brings Vast Digital Health Experience Focused on Demonstrable Growth and Commercial Excellence NEW YORK , April 25, 2023 /PRNewswire/ -- PAVmed Inc....
PAVmed Digital Health Subsidiary, Veris Health, to Present Comprehensive Meta-analysis on Impact of Remote Patient Monitoring in Oncology at HIMSS PR Newswire Company presenting at highly influential HIMSS23 Global Health Conference, today, April 19, 2023 from 11:30 a.m....
2023-04-18 03:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Lucid Diagnostics to Present at 22nd Annual Needham Virtual Healthcare Conference PR Newswire NEW YORK , April 17, 2023 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diag...
2023-03-31 14:17:57 ET Shares of medical diagnostics company Lucid Diagnostics ( NASDAQ: LUCD ) rose ~6% on Friday after Medicare Administrative Contractor Palmetto GBA finalized Local Coverage Determination for molecular testing of certain upper gastrointestinal lesions. ...
Lucid Diagnostics Provides Update on Newly Published Future Effective Medicare Local Coverage Determination on Molecular Testing for Detection of Esophageal Precancer and Cancer PR Newswire Foundational LCD, to be effective May 14, 2023 , incorporates key feedback to 2022 dr...
2023-03-29 21:15:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
News, Short Squeeze, Breakout and More Instantly...
Lucid Diagnostics Announces Record Quarterly EsoGuard® Test Volume PR Newswire Quarterly EsoGuard ® test volume increased 31 percent sequentially NEW YORK , July 23, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("L...
Lucid Diagnostics Launches New Corporate Website PR Newswire NEW YORK , July 11, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and majority-ow...
Lucid Diagnostics Announces Positive Data from its ESOGUARD BE-1 Prospective, International, Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing in a Screening Population PR Newswire Prospective screening study demonstrates excellent EsoGuard s...